FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
07/01/2018
0:00
NaN:NaN:NaN
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.
Released on December 21, 2017
Mais episódios de "FDA Drug Information Updates"
Não percas um episódio de “FDA Drug Information Updates” e subscrevê-lo na aplicação GetPodcast.